# Rilvegostomig

Source: https://onco.cc/drugs/rilvegostomig/  
OnCo record `rilvegostomig` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Rilvegostomig is an experimental bispecific antibody from AstraZeneca in phase 2 trials for non-small-cell lung cancer, aimed at PD-1 and TIGIT.

## Summary

Rilvegostomig (AZD2936) is a bispecific antibody developed by AstraZeneca. Its targets are PD-1 and TIGIT (the sponsor names TIGIT x PD-1). The sponsor states: Rilvegostomig (AZD2936) is an anti-TIGIT/anti-PD-1 bispecific antibody given intravenously as monotherapy to enhance anti-tumour immune response in advanced/metastatic NSCLC with PD-L1 expression. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer. The largest, NCT04995523, plans to enrol 212 participants (actual) with primary completion was scheduled for 2026-08-28 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Code: AZD2936
- Modality: bispecific antibody
- Mechanism: Rilvegostomig (AZD2936) is an anti-TIGIT/anti-PD-1 bispecific antibody given intravenously as monotherapy to enhance anti-tumour immune response in advanced/metastatic NSCLC with PD-L1 expression.

## Sources

- ClinicalTrials.gov: trials of Rilvegostomig: https://clinicaltrials.gov/search?intr=Rilvegostomig

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- targets: [PD-1](https://onco.cc/targets/pd1/), [TIGIT](https://onco.cc/targets/tigit/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/), [Compugen](https://onco.cc/companies/compugen/)
- trials: [A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer](https://onco.cc/trials/nct06868277/), [A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous N](https://onco.cc/trials/nct06627647/), [A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-s](https://onco.cc/trials/nct06692738/), [A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies](https://onco.cc/trials/nct05123482/), [A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer](https://onco.cc/trials/nct06764875/), [A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following C](https://onco.cc/trials/nct06564844/), [A Platform Study in Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct06996782/), [A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC](https://onco.cc/trials/nct04995523/), [A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma](https://onco.cc/trials/nct07069712/), [A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct07098338/), [A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)](https://onco.cc/trials/nct07221253/), [A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct07115043/), [An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC](https://onco.cc/trials/nct07720284/), [DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC](https://onco.cc/trials/nct06989112/), [Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma](https://onco.cc/trials/nct05702229/), [Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer](https://onco.cc/trials/nct06467357/), [Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma](https://onco.cc/trials/nct06921785/), [Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥](https://onco.cc/trials/nct06357533/), [Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)](https://onco.cc/trials/nct06109779/), [Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2](https://onco.cc/trials/nct07431281/), [Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)](https://onco.cc/trials/nct05489211/), [Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer](https://onco.cc/trials/nct05775159/)
- roadmaps: [Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials](https://onco.cc/roadmaps/gallbladder-cancer-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/rilvegostomig.json